A 29-amino-acid peptide corresponding to the first 29 residues of natural GHRH (1-44). The shortest fragment that retains full biological activity. FDA-approved as a diagnostic agent for GH deficiency and formerly approved for GH-deficient children.
Sermorelin (GHRH 1-29) is a 29-amino-acid peptide that is the biologically active fragment of the 44-amino-acid growth hormone-releasing hormone. It was the first GHRH-based therapeutic developed, demonstrating that only the first 29 residues are needed for full GHRH receptor activation.
Unlike exogenous GH injection, sermorelin stimulates the pituitary to produce and release its own GH through the natural GHRH receptor pathway. This preserves the physiological pulsatile pattern of GH secretion and allows the body's feedback mechanisms to prevent excess GH levels.
Sermorelin is the shortest functional fragment of GHRH — the first 29 amino acids of the 44-amino-acid native hormone — and retains full biological activity at the GHRH receptor. It was FDA-approved in 1997 as a diagnostic agent for GH deficiency in children (marketed as Geref Diagnostic) but was withdrawn from the market in 2008 for commercial reasons, not safety concerns. Despite the FDA withdrawal, sermorelin remained one of the most widely prescribed GH-stimulating peptides in anti-aging and functional medicine.
Sermorelin's appeal lies in its physiological approach to GH optimization. Rather than administering exogenous growth hormone directly (which suppresses the body's own GH production via negative feedback), sermorelin stimulates the pituitary gland to produce and release its own GH in natural pulsatile patterns. This preserves the hypothalamic-pituitary feedback loop and is considered a safer long-term approach than direct GH replacement.
As of early 2026, sermorelin remains available for compounding — it was not placed on the FDA's Category 2 restricted list, likely because it had prior FDA approval and a well-established safety profile. It continues to be one of the most commonly prescribed peptides for age-related GH decline.
Sermorelin is the prototypical GHRH receptor agonist. It activates the same Gs-cAMP-PKA cascade as native GHRH, stimulating both GH gene transcription and release of stored GH granules from somatotrophs.
| Pathway | Effect | Significance |
|---|---|---|
| GHRH-R agonism | Full activation of GHRH receptor with first 29 residues | Identical signaling to native GHRH 1-44 |
| Pulsatile GH | Short half-life produces natural GH pulses | Preserves physiological GH secretion pattern |
| IGF-1 stimulation | GH-mediated hepatic IGF-1 production | Downstream growth, repair, and metabolic effects |
| No GH suppression | Works through natural axis, not exogenous replacement | Body's feedback prevents excess GH |
| Study | Design | Findings | Level |
|---|---|---|---|
| GH deficiency diagnosis | FDA-approved diagnostic | IV sermorelin measures pituitary GH reserve. Normal response rules out pituitary cause of GH deficiency. | Level I |
| Pediatric GH deficiency | Former FDA indication | Stimulated growth in GH-deficient children. Withdrawn from market (2008) for commercial reasons, not safety. | Level I |
| Anti-aging | Clinical studies | Increased IGF-1, improved body composition, sleep quality in adults. Off-label use common. | Level II-III |
Well-established safety profile: Sermorelin has the most extensive human safety data of any GH secretagogue, having been FDA-approved (albeit for diagnostic use) and used clinically for decades. No serious adverse events have been attributed to sermorelin at therapeutic doses in the published literature.
Injection site reactions: Pain, redness, or swelling at the subcutaneous injection site are the most commonly reported side effects. These are typically mild and self-limiting.
Flushing and headache: Transient facial flushing, dizziness, and headache have been reported, particularly with the first few doses. These effects typically diminish with continued use.
GH-related effects: Water retention, joint stiffness, and carpal tunnel-like symptoms can occur if GH levels are elevated significantly, though these are less common with sermorelin than with direct GH administration because the pituitary's natural regulatory mechanisms remain intact.
Advantages over direct GH: Because sermorelin works through the body's own GH production pathway, it maintains the pulsatile pattern of GH release and preserves negative feedback regulation. This means the risk of GH excess (and its associated side effects) is lower than with exogenous GH injection.
| Jurisdiction | Status |
|---|---|
| FDA | Approved as diagnostic (Geref). Former therapeutic approval withdrawn 2008 (commercial, not safety). |
| WADA | Banned under S2 |
| Status | Largely replaced by CJC-1295 and tesamorelin in clinical use |
| Feature | Sermorelin | CJC-1295 |
|---|---|---|
| Length | 29 amino acids | 30 amino acids |
| Half-life | 10-20 minutes | 6-8 days (with DAC) |
| Dosing | Daily injection | Weekly injection |
| Modification | None (natural sequence) | DAC for albumin binding |
| FDA status | Approved (diagnostic) | Not approved |